Lean Life Science and Cancer Research Horizons have launched a new Oncology Development Programme
Do you have emerging oncology innovations that have the potential to improve diagnosis and treatment of cancer?
Lean Life Science and Cancer Research Horizons have launched a new Oncology Development Programme focused on accelerating high impact novel cancer innovations. Called ODP2, it is a fully-funded programme to identify and accelerate novel oncology innovations into commercially attractive assets.
Open to the UK academic community and UK-based early-stage companies with an oncology-focused innovation (including therapeutic, diagnostic, digital, medtech), the programme is supported by unique insights from a collaboration of leading global pharma companies, CROs, and subject matter experts in residence from across the global oncology R&D ecosystem.
ODP2 will Identify, de-risk and catalyse commercially viable UK-based oncology innovations to improve diagnosis and treatment of cancer and accelerate the translation of emerging cancer research for patient benefit.
Developed and directed by Lean Life Science founder, Ned Wakeman, participation in ODP2 will give the next big UK-based breakthroughs in oncology access to bespoke expert scientific review, clinical study design, technical gap analysis, financial / business value modelling and integrated project planning.
If you think that any of the innovations in your network would benefit from participation in ODP2 please share this information.
Full details of ODP2 can be found here, along with dates of Q&A webinars.
